青海春天药用资源科技股份有限公司 第九届董事会第四次会议决议公告 股票代码：600381 股票简称：青海春天 公告编号：2023-031 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 青海春天药用资源科技股份有限公司（以下简称"公司"）董事会于2023年12月7 日以电子邮件方式发出召开第九届董事会第四次会议通知，会议于2023年12月11日上 午10：00时以现场表决结合通讯表决的形式召开。本次会议应到董事7人，实际到会董 事7人。会议由公司董事长张雪峰先生主持，公司监事、高级管理人员列席。本次会议 的召集、召开及表决方式符合《公司法》及《公司章程》等的有关规定，所形成决议 合法有效。 二、董事会会议审议情况 经与会董事认真审议，本次会议审议通过了如下议案： （三）《修订公司<董事会议事规则>的议案》 表决情况：7 票同意，0 票反对，0 票弃权。 修订后的公司《董事会议事规则》详见上海证券交易所网站（www.sse.com.cn）。 本议案尚需提交公司股东大会审议。 （四）《修订公司<董事会审计委 ...

青海春天药用资源科技股份有限公司股东大会议事规则 青海春天药用资源科技股份有限公司 股东大会议事规则 （2023 年 12 月修订） 第一章 总则 第一条 为保证青海春天药用资源科技股份有限公司（以下简称"我公司"、 "公司"）股东大会依法行使职权、保证公司股东依法行使权利,现根据《中华人 民共和国公司法》(以下简称《公司法》)、《中华人民共和国证券法》(以下简称 《证券法》)、中国证券监督管理委员会《上市公司股东大会规则》、《独立董事 管理办法》、《上海证券交易所股票上市规则》、《上海证券交易所上市公司自律监 管指引第 1 号-规范运作》及我公司《章程》的规定,制定本规则。 第二条 股东大会应当在《公司法》和公司章程规定的范围内行使职权，股 东大会是公司的权力机构。公司董事会应当切实履行职责，认真、按时组织股东 大会，公司全体董事应当勤勉尽责，确保股东大会正常召开和依法行使职权。 第三条 公司股东大会分为年度股东大会和临时股东大会。 年度股东大会每年召开一次,应当于上一会计年度结束后的 6 个月内举行。 临时股东大会不定期召开,出现《公司法》第一百条规定的应当召开临时股东大 会的情形时,临时股东大会应当在 ...

青海春天独立董事管理及工作制度 青海春天药用资源科技股份有限公司 独立董事管理及工作制度 （2023 年 12 月制定） 第二章 独立董事的任职资格和任免 青海春天药用资源科技股份有限公司（"青海春天"、"公司"）为充分 发挥独立董事在公司治理中的作用，提高公司治理水平和质量，维护公司整 体利益及中小投资者的利益，现根据《中华人民共和国公司法》（"《公司法 》"）《中华人民共和国证券法》、国务院办公厅《关于上市公司独立董事制 度改革的意见》、中国证券监督管理委员会（"中国证监会"）《上市公司独 立董事管理办法》（"《管理办法》"）《上市公司治理准则》《上海证券交 易所股票上市规则（2023 年 8 月修订）》《上海证券交易所上市公司自律 监管指引第 1 号——规范运作（2023 年 8 月修订）》《上海证券交易所信 息披露管理办法》《公司章程》等的有关规定并结合公司实际情况，制定本 制度。 第一章 总 则 第一条 公司需建立独立董事制度。独立董事制度应当符合我国法律、行 政法规、中国证监会规定和上海证券交易所业务规则的规定，有利于公司的 持续规范发展、不得损害公司利益。公司需为独立董事依法履职提供必要保 障。 ...

青海春天独立董事专门会议制度 青海春天药用资源科技股份有限公司 独立董事专门会议制度 （2023 年 12 月制订） 青海春天药用资源科技股份有限公司（"青海春天"、"公司"）为充分发挥 独立董事在公司治理中的作用，提高公司治理水平和质量，维护公司整体利益及 中小投资者的利益，现根据《中华人民共和国公司法》（"《公司法》"）《中华 人民共和国证券法》、国务院办公厅《关于上市公司独立董事制度改革的意见》、 中国证券监督管理委员会（"中国证监会"）《上市公司独立董事管理办法》（"《管 理办法》"）《上市公司治理准则》《上海证券交易所股票上市规则（2023 年 8 月修订）》《上海证券交易所上市公司自律监管指引第 1 号——规范运作（2023 年 8 月修订）》、公司《章程》《独立董事管理及工作制度》等的有关规定并结 合公司实际情况，制定本制度。 第一条 独立董事专门会议（"专门会议"）是指由公司全部在任独立董事参 加的会议。独立董事通过参加会议，以维护公司和中小股东利益为目标，充分发 挥各自的专业知识，从独立判断的角度对所研讨的公司事项进行讨论，并形成有 关的意见提交公司董事会。 第二条 专门会议每个自然年至少召 ...

证券代码：600381 证券简称：青海春天 公告编号：2023-033 青海春天药用资源科技股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第一次临时股东大会 召开的日期时间：2023 年 12 月 28 日 14 点 30 分 召开地点：青海省西宁市城北区生物园区经二路 12 号 4 楼会议室 (五) 网络投票的系统、起止日期和投票时间。 股东大会召开日期：2023年12月28日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 12 月 28 日 至 2023 年 12 月 28 日 采用上海证券交易所网络投票系统，通过交易系 ...

青海春天药用资源科技股份有限公司董事会议事规则 第二章 董事会的组成 第二条 公司董事会是公司经营管理的决策机构，在《公司章程》和股东大 会的授权范围内负责公司发展目标和重大经营活动的决策。 第三条 董事会由七名董事组成，其中董事四名，独立董事三名（其中至少 一名为会计专业人士）。董事会设董事长一人，由全体董事的过半数选举产生， 是公司法定代表人。 第四条 公司董事会下设战略委员会、提名委员会、审计委员会、薪酬与考 核委员会四个专门委员会，各委员会依据《公司章程》以及各自工作规则运作。 青海春天药用资源科技股份有限公司 董事会议事规则 （2023 年 12 月修订） 第一章 总则 第一条 为进一步规范青海春天药用资源科技股份有限公司（以下简称"我 公司"）董事会的议事方式和决策程序，促使董事和董事会有效地履行其职责， 提高董事会规范运作和科学决策水平，根据《公司法》、《证券法》、《上市公司治 理准则》、《上海证券交易所股票上市规则》、《上海证券交易所上市公司自律监管 指引第 1 号-规范运作》及《公司章程》等有关规定，制订本规则。 第五条 董事会下设董事会秘书办公室（以下简称"董秘办"），协助董事 长处理董事 ...

股票代码：600381 股票简称：青海春天 公告编号：2023-030 青海春天药用资源科技股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 股东 | 是否为控 | 本次质 | 是否为 | 是否补 | 质押起 | 质押到 | | 占其所 | 占公司 | 质押融 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股股东 | 押股数 | 限售股 | 充质押 | 始日 | 期日 | 质权人 | 持股份 | 总股本 | 资资金 | | | | | | | | | | 比例 | 比例 | 用途 | | 西 藏 | 是 | 2,000 | 否 | 否 | 2023- | 2024- | 云南国 际 | 10.60% | 3.41% | 项目开 | | 荣恩 | | 万股 | | | 11-21 | 11-20 | 信托有 限 | | | 发 | | | | | | | | | 公司 | | ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥53,289,081.38, representing a 129.10% increase compared to the same period last year[5]. - Total operating revenue for the first three quarters of 2023 reached ¥160,712,654.06, an increase of 24.93% compared to ¥128,645,957.46 in the same period of 2022[21]. - The net profit attributable to shareholders was -¥19,740,514.59, with a year-to-date net profit of -¥70,331,228.73[5]. - Net profit for the first three quarters of 2023 was a loss of ¥68,576,421.15, compared to a loss of ¥75,403,109.87 in the same period of 2022, showing an improvement of 9.73%[22]. - Basic and diluted earnings per share for Q3 2023 were both -¥0.034, with a year-to-date figure of -¥0.120[6]. - Basic and diluted earnings per share for the first three quarters of 2023 were both -0.120, slightly better than -0.128 in the same period of 2022[23]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥8,962,743.45[6]. - Net cash flow from operating activities for Q3 2023 was $8,962,743.45, a significant improvement from a net outflow of $20,357,176.51 in Q3 2022[26]. - Cash paid for operating activities totaled $170,177,883.30, down from $196,434,823.09 in Q3 2022[26]. - Total cash inflow from investment activities was $60,089,667.08, compared to $623,921,075.12 in the same period last year[26]. - Cash outflow from investment activities totaled $71,014,967.19, resulting in a net cash flow of -$10,925,300.11 for Q3 2023, down from a positive $34,780,001.12 in Q3 2022[26]. - The company reported a net cash decrease of $6,749,165.61 for Q3 2023, contrasting with an increase of $14,883,799.99 in Q3 2022[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,520,345,780.92, a decrease of 2.49% from the end of the previous year[6]. - As of September 30, 2023, the total assets of the company amounted to CNY 1,520,345,780.92, a decrease from CNY 1,559,229,152.99 at the end of 2022, reflecting a decline of approximately 2.1%[15]. - The company's current assets totaled CNY 761,618,090.69, down from CNY 816,003,528.06, indicating a decrease of about 6.7%[17]. - Total liabilities as of the end of the third quarter of 2023 amounted to ¥55,992,026.91, compared to ¥26,298,977.83 at the end of the same period in 2022, indicating a significant increase[22]. - The total liabilities of the company were not explicitly stated, but current liabilities included accounts payable of CNY 16,467,410.00, up from CNY 2,672,389.74, showing a significant increase[17]. Equity and Investments - The equity attributable to shareholders decreased by 4.59% to ¥1,462,600,343.67 compared to the end of the previous year[6]. - Total equity attributable to shareholders of the parent company was ¥1,462,600,343.67, down from ¥1,532,931,572.40 in the previous year[22]. - The company has a long-term equity investment valued at CNY 172,708,109.45, slightly down from CNY 172,824,966.22, indicating a marginal decrease[17]. Operational Highlights - The company reported a significant increase in revenue from liquor and traditional Chinese medicine services as the main driver for the revenue growth[10]. - Research and development expenses for the first three quarters of 2023 were ¥7,554,555.90, slightly up from ¥7,356,360.50 in 2022, indicating continued investment in innovation[21]. - The company reported a financial expense of -¥74,903.47 in the first three quarters of 2023, a significant improvement compared to ¥691,604.64 in the same period of 2022[21]. - The company has not reported any new product launches or significant market expansion strategies during this period[21]. - The company did not report any new product launches or significant market expansions during this quarter[28]. Other Financial Metrics - Non-recurring losses for the reporting period included a loss from the disposal of non-current assets amounting to -¥19,388.28[8]. - The company received government subsidies totaling ¥171,826.34 during the reporting period[8]. - The weighted average return on net assets was -1.3%, a slight increase of 0.18 percentage points compared to the previous year[6]. - Cash and cash equivalents were reported at CNY 161,941,283.99, a decrease from CNY 168,690,449.60, representing a decline of approximately 4.4%[15]. - Accounts receivable increased to CNY 62,767,471.38 from CNY 55,367,840.10, marking an increase of about 13.5%[15]. - Inventory decreased to CNY 304,777,334.66 from CNY 333,495,051.35, reflecting a decline of approximately 8.6%[15]. - The company's non-current assets totaled CNY 758,727,690.23, an increase from CNY 743,225,624.93, indicating a growth of about 2.3%[17]. - The company’s fixed assets increased to CNY 280,254,004.18 from CNY 274,955,062.12, reflecting a growth of about 1.2%[17]. - The company reported a decrease in other receivables to CNY 10,522,211.79 from CNY 11,995,395.78, a decline of approximately 12.3%[15].

股票代码：600381 股票简称：青海春天 公告编号：2023-029 青海春天药用资源科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 三、 参加人员 重要内容提示： 问题征集方式：投资者可于 2023 年 10 月 12 日 15:00 前，提前将需要了解的 情况和有关问题通过电子邮件发送至公司邮箱 investor@verygrass.com。公司将在本 次业绩说明会上对投资者普遍关注的问题进行交流。 一、 说明会类型 青海春天药用资源科技股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日在 上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体披露了《2023 年半年度 报告》。 为了便于广大投资者更全面深入了解公司 2023 年半年度生产经营、发展情况及未 来规划等，公司决定通过网络互动的方式召开 2023 年半年度业绩说明会，就投资者普 遍关注的问题进行交流。 二、 说明会召开的时间、地点 1.召开时间：2023 年 10 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 107.42 million, representing a 1.93% increase compared to CNY 105.39 million in the same period last year[21]. - The net profit attributable to shareholders of the listed company was a loss of CNY 50.59 million, compared to a loss of CNY 48.94 million in the previous year, indicating a continued decline in profitability[21]. - The net cash flow from operating activities was a negative CNY 24.47 million, worsening from a negative CNY 16.24 million in the same period last year[21]. - The total assets at the end of the reporting period were CNY 1.53 billion, down 1.65% from CNY 1.56 billion at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company decreased to CNY 1.48 billion, a decline of 3.3% from CNY 1.53 billion at the end of the previous year[21]. - The basic earnings per share for the first half of 2023 was -CNY 0.086, slightly worse than -CNY 0.083 in the same period last year[22]. - The weighted average return on net assets was -3.35%, a decrease of 0.63 percentage points compared to -2.72% in the previous year[22]. - Total revenue for the reporting period was CNY 107.42 million, a 1.93% increase year-on-year, with core business revenue at CNY 103.22 million, growing 0.44%[36]. - Sales expenses rose to CNY 89.24 million, a 29.23% increase year-on-year, contributing to an operating loss of CNY 47.06 million[36]. Business Operations and Strategy - The company has not disclosed any plans for new product development or market expansion in this report[21]. - The company is focusing on upgrading the "Tinghua" and "Duhua" high-end liquor products, with new product launches expected in the third quarter[30]. - The company is enhancing its marketing efforts and expanding distribution channels to improve sales performance[29]. - The company is optimizing and regulating its distributor network to support future marketing and sales efforts[30]. - The company has established a strategic partnership with Yibin Tinghua for exclusive sales of high-end liquor series, focusing on self-operated and distributor sales channels[32]. - The company is enhancing brand influence through multi-channel marketing efforts, including major media outlets and targeted advertising[39]. - The company continues to strengthen cooperation with distributors to expand sales channels and ensure mutual benefits[39]. - The company has opened 9 "Tinghua" experience stores in cities including Beijing, Tianjin, and Chengdu, with 7 more under construction, enhancing consumer engagement with the product[31]. Market Environment - The domestic GDP for the first half of 2023 was 59.30 trillion yuan, with a year-on-year growth of 5.5%[26]. - The retail sales of consumer goods reached 22.76 trillion yuan, a year-on-year increase of 8.2%[26]. - The government has introduced favorable policies for the traditional Chinese medicine industry, providing a positive market environment[27]. Financial Health and Risks - The report includes a risk statement regarding potential external environment risks and internal management risks that may affect future performance[6]. - The company faces risks including policy market risks, market competition risks, and internal management risks, which may impact strategic development and operational plans[55]. - The company plans to enhance internal control execution and supervision to mitigate risks related to product quality, food safety, and decision-making errors[56]. - The company maintains a healthy financial structure with low debt levels, ensuring smooth operations and strategic planning[34]. Research and Development - Research and development expenses increased by 9.21% to CNY 3.25 million, indicating a focus on innovation[42]. - The company has applied for an international invention patent related to a new alcohol composition aimed at health benefits, indicating significant future product potential[39]. Subsidiaries and Investments - The company has a total of 9 subsidiaries included in the consolidated financial statements for 2023[138]. - The company established two joint ventures in Tibet, each holding 51% equity, to enhance sales channels, which will aid future business development[40]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 55,530[82]. - The largest shareholder, Tibet Rong'en Technology Co., Ltd., holds 194,115,194 shares, accounting for 33.07% of the total shares[85]. - The second-largest shareholder, Dantian, holds 56,762,789 shares, representing 9.67% of the total shares[85]. - No profit distribution or capital reserve transfer plans were proposed for the half-year, with no dividends or stock bonuses planned[65]. Compliance and Governance - The financial statements are prepared based on the assumption of going concern, with no significant doubts about the company's ability to continue operations[139]. - The company has not reported any significant changes in its share capital structure during the reporting period[81]. - The company has not reported any major changes in the board of directors or senior management during the reporting period[87]. Accounting Policies - The company follows specific accounting policies for bad debt provisions, inventory valuation, and revenue recognition, among others[140]. - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position as of June 30, 2023[141]. - The company recognizes revenue when control of goods or services is transferred to customers, typically at the point of delivery[191].